

GILEAD SCIENCES INC

Form 3

November 21, 2016

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Meyers James R

(Last)

(First)

(Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

11/10/2016

3. Issuer Name **and** Ticker or Trading Symbol
GILEAD SCIENCES INC [GILD]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

GILEAD SCIENCES,
INC.,Â 333 LAKESIDE DRIVE

(Street)

(Check all applicable)

☐ Director ☐ 10% Owner☒ X Officer ☐ Other

(give title below) (specify below)

EVP Worldwide Commercial Ops

6. Individual or Joint/Group Filing(Check Applicable Line)

☒ X Form filed by One Reporting Person☐ Form filed by More than One Reporting Person

FOSTER CITY,Â CAÂ 94404

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned1. Title of Security
(Instr. 4)2. Amount of Securities Beneficially Owned
(Instr. 4)3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Common Stock

6,726

D

Â

Common Stock

121,151

I

By Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and Expiration Date
(Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)

4. Conversion or Exercise Price of

5. Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Edgar Filing: GILEAD SCIENCES INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Non-qualified Stock Option (Right to Buy)	Â <u>(3)</u>	10/22/2017	Common Stock	60,000	\$ 21	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(3)</u>	01/30/2018	Common Stock	100,000	\$ 21.575	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(3)</u>	01/21/2019	Common Stock	60,000	\$ 23.6	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(3)</u>	07/29/2019	Common Stock	60,000	\$ 24.905	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(3)</u>	01/28/2020	Common Stock	53,200	\$ 23.755	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(4)</u>	01/20/2021	Common Stock	67,200	\$ 19.085	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(4)</u>	01/26/2022	Common Stock	48,000	\$ 24.295	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(4)</u>	02/01/2023	Common Stock	34,890	\$ 40.56	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(4)</u>	02/01/2024	Common Stock	25,780	\$ 80.65	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(4)</u>	02/01/2025	Common Stock	17,590	\$ 104.83	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(4)</u>	02/01/2026	Common Stock	17,560	\$ 84.05	D	Â
Non-qualified Stock Option (Right to Buy)	Â <u>(4)</u>	08/10/2026	Common Stock	15,450	\$ 78.9	D	Â
Restricted Stock Unit	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	9,780	\$ <u>(1)</u>	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Meyers James R GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY, CA 94404	Â	Â	Â EVP Worldwide Commercial Ops	Â

Signatures

/s/ Marissa Song by Power of Attorney for James R.
Meyers

11/21/2016

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- (2) The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
- (3) The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- (4) The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.